[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.17.193. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 21, 2001

Nevirapine and Postexposure Prophylaxis for Human Immunodeficiency Virus

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(7):883. doi:10.1001/jama.285.7.879

To the Editor: Two cases were recently reported in THE JOURNAL of health care workers with possible exposure to the human immunodeficiency virus (HIV) who developed adverse reactions after receiving multiple doses of nevirapine, zidovudine, and lamivudine as a postexposure prophylaxis (PEP) regimen.1,2 One patient developed fulminant hepatic failure resulting in liver transplant, and the other patient developed rash, eosinophilia, and other systemic symptoms. Both patients have since recovered. The authors believe that nevirapine was responsible for both these adverse reactions, although the precise etiology of these reactions is unknown. Since no clinical trials have been conducted that would assess the risks or establish the efficacy of using nevirapine for PEP, the risks remain undefined. Postexposure prophylaxis is not an approved indication for nevirapine and Boehringer Ingelheim (BI) does not recommend using it for PEP.

First Page Preview View Large
First page PDF preview
First page PDF preview
×